The accelerated approval of Biogen’s Aduhelm has caught the eye of AbbVie, which plans to push an Alzheimer’s disease candidate that potentially has a better safety profile into the clinic by year’s end or early next year.

Investors have flocked to T-knife Therapeutics, which has been taking aim at solid tumors, an area where cell therapies have struggled to perform as well as they have in some blood cancers. Just last year, the biotech raised €66 million ($78 million) and now has reeled in a further $110 million to support a multifront push into clinical trials.

Only a few months after Bioventus CEO Ken Reali described to Fierce Medtech the company’s plans to focus on growing its business in order to recover from pandemic-induced setbacks into a “new normal,” the orthopedic therapy developer is making good on those plans.

Flying high from a second quarter that saw sales jump more than 40%, NuVasive is setting itself up for an even bigger second half of the year, thanks to a newly bestowed FDA clearance for its Pulse spine surgery platform.

Digital therapeutics have been pitched for conditions ranging from substance abuse to ADHD, but now Biofourmis is putting forward its program for heart failure—and the FDA hopes to expedite its use in the clinic.

No one knows why some people with Parkinson’s will have their disease turn severe while others may not, but artificial intelligence researchers at IBM and the Michael J. Fox Foundation think they may have cracked the code.

The cytokine TSLP is an immune system protein known to play a role in some allergic diseases, and a research team at the University of Pennsylvania has been investigating whether it also influences insulin resistance, making it a possible target for treating Type 2 diabetes. Now, they’ve discovered that TSLP promotes weight loss in mice—and it does so in an unusual way.

Great progress has been made in perfecting the delivery of gene therapies using viral vectors, lipid nanoparticles and other technologies. But there are still improvements needed on the cargo itself, to better control the expression of genes to boost safety and efficacy.

Medtronic has its heart set on ensuring that its insertable cardiac monitors are as accurate as possible, and a new pair of artificial intelligence algorithms might be just the ticket.

Annovis Bio wants its Alzheimer’s disease therapy to be better than Biogen’s Aduhelm, but the latest data shows the drug did not improve dementia symptoms, problem-solving, orientation or judgment, among other data points.